Brief: Biocytogen Enters Into Agreement With Merck To Advance Antibody-Conjugated Lipid-Based Delivery Solutions
04/09/2025 01:03
Sept 3 (Reuters) - Biocytogen Pharmaceuticals Beijing Co Ltd 2315.HK: BIOCYTOGEN ENTERS INTO AGREEMENT WITH MERCK TO ADVANCE ANTIBODY-CONJUGATED LIPID-BASED DELIVERY SOLUTIONS Source text: ID:nBw1VLP97a Further company coverage: 2315.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck KGaA
See all newsUS stocks weekly: AI reality
US stocks weekly: AI reality
Brief: Bio-Techne Co Will Be Required To Pay To Merck KGaA Termination Fee Equal To $230.5 Million If Deal Terminated Under Certain Circumstances - SEC Filing
Press Digest: Financial Times - June 26
US STOCKS-Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook